ClinicalTrials.gg
RecruitingNCT07701369REFERENCE-AIUpdated Jul 28, 2026

Relevance of Artificial Intelligence-Assisted Echocardiography for Left Ventricular Ejection Fraction Assessment in Geriatric Patients

An interventional study of AutoEF-AI Assessment and Standard Echocardiography (Reference method) in Heart Failure, sponsored by Gérond'if. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Gérond'if · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Non-randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 448 studies in Heart Failure with a site in France — 90 open to participants now, 116 under way, 16 of them phase 3. Heart Failure · France.

Planned enrollment
163rd of 282
130 · median 196
Started
2026
with 26 others
No phase
176 of 448
47 open now
Primary completion
2028-06
later than 77 of 115 live
Registered
437th of 448
by date

Among the 448 studies in Heart Failure with a site in France, this one is the 163rd largest by planned enrollment of the 282 interventional ones that give a count, is one of 27 that started in 2026, is one of 176 with no phase, reaches primary completion later than 77 of the 115 other live ones, and was the 437th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

90 of the 448 studies in Heart Failure with a site in France are open now. Recruiting first, the newest first:

84 more — sign in →

All 90 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Heart Failure with a site in France, or all of them as a file.
02

Study summary

Heart failure (HF) is the leading cause of hospitalization among adults aged 80 years and older and represents a major diagnostic challenge in geriatric medicine due to frequently atypical clinical presentations and the presence of multiple comorbidities. Although transthoracic echocardiography (TTE) with measurement of left ventricular ejection fraction (LVEF) remains the gold standard for cardiac functional assessment, access to echocardiography is often limited in geriatric wards.

Recent advances in artificial intelligence (AI) have enabled the development of portable ultrasound devices and automated image analysis software capable of providing reliable and reproducible LVEF measurements. AI-assisted automated LVEF assessment (AutoEF-AI) may therefore represent a valuable alternative to conventional echocardiography for the cardiac evaluation of older patients with heart failure.

Read the detailed description

Prospective, single-center interventional study comparing two methods of left ventricular ejection fraction measurement in patients aged 75 years and older hospitalized for acute heart failure.Each hemodynamically stable participant will undergo two echocardiographic examinations performed within 24 hours:

  • Standard Echocardiography (Reference Method)
  • AI-assisted automated LVEF assessment (AutoEF-AI)
03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart failure
  • Artificial Intelligence-Assisted Echocardiography
  • Artificial Intelligence
  • Echocardiography
  • Left Ventricular Ejection Fraction
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥75 years.
  • Hospitalization in a geriatric unit for acute heart failure according to the 2021 ESC diagnostic criteria.
  • Hemodynamic stability at the time of echocardiographic examination.
  • Ability to understand study information, provide written , and willingness to participate.
  • Affiliation with, or beneficiary of, a health insurance/social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Hemodynamic instability preventing echocardiographic assessment.
  • to transthoracic echocardiography.
  • Patients under legal protection (guardianship, curatorship, or judicial protection measures) or unable to provide .
  • Refusal to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
130 participants (estimated)

Study arms

  • Other
    Standard Echocardiography (Reference method)

    The standard echocardiography will be performed by a cardiologist as part of routine clinical care.

    Diagnostic Test: Standard Echocardiography (Reference method)

  • Experimental
    AutoEF-AI Assessment

    AI-assisted automated LVEF assessment

    Diagnostic Test: AutoEF-AI Assessment

Interventions

  • Diagnostic testAutoEF-AI Assessment

    Performed by a geriatrician who has completed a one-day practical training session and combines: * A handheld ultrasound device providing real-time image acquisition guidance for obtaining apical views. * Us2.ai software for automated LVEF analysis. The geriatrician is blinded to results of the gold standard echocardiography performed by the cardiologist.

  • Diagnostic testStandard Echocardiography (Reference method)

    The standard echocardiography will be performed by an expert cardiologist as part of routine clinical care and will serve as the gold standard

06

What researchers measure

Primary outcomes

  1. Agreement between LVEF measured using AutoEF-AI and LVEF measured using standard echocardiography.

    Agreement will be assessed using: * Intraclass Correlation Coefficient (ICC) * Spearman correlation coefficient * Bland-Altman analysis * Weighted kappa coefficient for the classification of patients according to LVEF categories (≤40%, 41-49%, and ≥50%)

    Time frame: At baseline

Secondary outcomes

  1. Diagnostic performance of AutoEF-AI for the detection of LVEF <50%, including sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy.

    Calculation of the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy of AutoEF-AI for identifying left ventricular ejection fraction (LVEF) below 50%, compared with the standard reference method.

    Time frame: At baseline

  2. Analysis of factors associated with agreement between the two methods

    Multiple linear regression model will be used to identify clinical and technical variables (age, sex, cardiovascular history, presence of a pacemaker, cardiac arrhythmias, image quality, comorbidities, etc.) associated with a significant discrepancy between LVEF measurements obtained using AutoEF-AI and standard echocardiography.

    Time frame: At baseline

  3. Feasibility of AutoEF-AI use by a geriatrician after a short training program

    * Success rate of valid image acquisition (i.e acquizition of analyzable apical views suitable for automated analysis) * Quality of the acquired images (image quality score and proportion of non-analyzable images) * Difficulties encountered during the use of the AutoEF-AI device

    Time frame: At baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2028, 23 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 23 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 14, 2026
StartActual
Jul 7, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07701369
Lead sponsor
Gérond'if
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Jul 7, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jul 28, 2026

Study contacts

Isabelle DUFOUR
Contact
isabelle.dufour@gerondif.org
+33 (0) 185781011
Prisca LUCAS, PhD MPH
Contact
prisca.lucas@gerondif.org
+33 (0)185737323
Olivier HANON, MD PhD
principal investigator · Geriatric Department, Broca hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion